MX383344B - Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. - Google Patents
Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.Info
- Publication number
- MX383344B MX383344B MX2017009122A MX2017009122A MX383344B MX 383344 B MX383344 B MX 383344B MX 2017009122 A MX2017009122 A MX 2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A MX 383344 B MX383344 B MX 383344B
- Authority
- MX
- Mexico
- Prior art keywords
- fluticasone propionate
- dry powder
- dose
- salmeterol xinafoate
- sub
- Prior art date
Links
- 229960000289 fluticasone propionate Drugs 0.000 title abstract 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title abstract 5
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005018 salmeterol xinafoate Drugs 0.000 title abstract 3
- 229940112141 dry powder inhaler Drugs 0.000 title abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105479P | 2015-01-20 | 2015-01-20 | |
| PCT/US2016/014072 WO2016118589A1 (en) | 2015-01-20 | 2016-01-20 | Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009122A MX2017009122A (es) | 2017-10-12 |
| MX383344B true MX383344B (es) | 2025-03-13 |
Family
ID=55443303
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009122A MX383344B (es) | 2015-01-20 | 2016-01-20 | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. |
| MX2021006751A MX2021006751A (es) | 2015-01-20 | 2017-07-12 | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006751A MX2021006751A (es) | 2015-01-20 | 2017-07-12 | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180015035A1 (enExample) |
| EP (1) | EP3247331A1 (enExample) |
| JP (1) | JP2018503687A (enExample) |
| KR (1) | KR20170103975A (enExample) |
| CN (1) | CN107530357A (enExample) |
| AR (1) | AR104771A1 (enExample) |
| AU (2) | AU2016209363B2 (enExample) |
| BR (1) | BR112017015353A2 (enExample) |
| CA (1) | CA2974125A1 (enExample) |
| CL (1) | CL2017001859A1 (enExample) |
| CO (1) | CO2017008395A2 (enExample) |
| EA (1) | EA201791632A1 (enExample) |
| HK (1) | HK1245125A1 (enExample) |
| IL (1) | IL253499A0 (enExample) |
| MA (1) | MA41378A (enExample) |
| MX (2) | MX383344B (enExample) |
| PE (1) | PE20171258A1 (enExample) |
| TW (1) | TW201628607A (enExample) |
| WO (1) | WO2016118589A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3054920T3 (pl) * | 2013-10-07 | 2021-07-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalator suchego proszku |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| EP3552646B1 (en) | 2016-11-18 | 2021-07-07 | Norton (Waterford) Limited | Drug delivery device with electronics |
| CN110201280B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药装置的吸嘴和吸入给药装置 |
| CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
| CN110201278B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
| CN110064110A (zh) * | 2019-05-29 | 2019-07-30 | 上海理工大学 | 一种容积旋钮式干粉储存吸入装置 |
| GB2585206B (en) * | 2019-07-01 | 2021-08-11 | Merxin Ltd | Portable inhaler |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| TWI224513B (en) | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Dose counter for medicament inhaler |
| PE20020067A1 (es) * | 2000-06-23 | 2002-02-05 | Norton Healthcare Ltd | Desaglomerador para inhalador de polvo seco accionado por la respiracion |
| AR030516A1 (es) * | 2000-08-31 | 2003-08-20 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
| EP2283817B1 (en) * | 2000-11-30 | 2016-05-18 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| GB0124523D0 (en) | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| CN1694689A (zh) | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| PT2435025T (pt) * | 2009-05-29 | 2016-11-11 | Pearl Therapeutics Inc | Administração, por via respiratória, de agentes activos |
| CN102573886A (zh) * | 2009-09-17 | 2012-07-11 | 相互制药公司 | 用抗病毒剂治疗哮喘的方法 |
| GB0919465D0 (en) | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
| DK2502644T3 (en) * | 2010-05-18 | 2015-02-02 | Ivax Pharmaceuticals Ireland | Dosistællere for inhalers, inhalers and shafts thereof |
| WO2011145109A1 (en) | 2010-05-20 | 2011-11-24 | Sun Pharma Advanced Research Company Ltd., | Dry powder inhalation composition |
| KR20130140358A (ko) * | 2012-06-14 | 2013-12-24 | 한미약품 주식회사 | 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 |
| EP2991626A1 (en) * | 2013-04-29 | 2016-03-09 | Sanofi SA | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| JP6387397B2 (ja) * | 2013-05-03 | 2018-09-05 | ダウ グローバル テクノロジーズ エルエルシー | 平衡制約反応のためのプロセス |
| PL3054920T3 (pl) | 2013-10-07 | 2021-07-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalator suchego proszku |
| BR112017007587A2 (pt) * | 2014-10-16 | 2018-01-30 | Teva Branded Pharmaceutical Products R&D Inc | processo para preparar uma formulação farmacêutica em pó seca e inalável |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
-
2016
- 2016-01-19 MA MA041378A patent/MA41378A/fr unknown
- 2016-01-20 CN CN201680011413.7A patent/CN107530357A/zh active Pending
- 2016-01-20 PE PE2017001234A patent/PE20171258A1/es unknown
- 2016-01-20 KR KR1020177023075A patent/KR20170103975A/ko not_active Ceased
- 2016-01-20 TW TW105101637A patent/TW201628607A/zh unknown
- 2016-01-20 HK HK18104726.3A patent/HK1245125A1/zh unknown
- 2016-01-20 JP JP2017556791A patent/JP2018503687A/ja active Pending
- 2016-01-20 EA EA201791632A patent/EA201791632A1/ru unknown
- 2016-01-20 US US15/544,900 patent/US20180015035A1/en not_active Abandoned
- 2016-01-20 AR ARP160100136A patent/AR104771A1/es active IP Right Grant
- 2016-01-20 AU AU2016209363A patent/AU2016209363B2/en not_active Ceased
- 2016-01-20 US US15/001,853 patent/US9415008B2/en active Active
- 2016-01-20 CA CA2974125A patent/CA2974125A1/en not_active Abandoned
- 2016-01-20 MX MX2017009122A patent/MX383344B/es unknown
- 2016-01-20 EP EP16706919.4A patent/EP3247331A1/en not_active Withdrawn
- 2016-01-20 WO PCT/US2016/014072 patent/WO2016118589A1/en not_active Ceased
- 2016-01-20 BR BR112017015353-0A patent/BR112017015353A2/en not_active Application Discontinuation
-
2017
- 2017-07-12 MX MX2021006751A patent/MX2021006751A/es unknown
- 2017-07-16 IL IL253499A patent/IL253499A0/en unknown
- 2017-07-18 CL CL2017001859A patent/CL2017001859A1/es unknown
- 2017-08-17 CO CONC2017/0008395A patent/CO2017008395A2/es unknown
-
2021
- 2021-05-04 AU AU2021202784A patent/AU2021202784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201628607A (zh) | 2016-08-16 |
| EP3247331A1 (en) | 2017-11-29 |
| CN107530357A (zh) | 2018-01-02 |
| US20160206559A1 (en) | 2016-07-21 |
| KR20170103975A (ko) | 2017-09-13 |
| BR112017015353A2 (en) | 2018-01-16 |
| CL2017001859A1 (es) | 2018-04-06 |
| CO2017008395A2 (es) | 2018-01-05 |
| US20180015035A1 (en) | 2018-01-18 |
| AR104771A1 (es) | 2017-08-16 |
| PE20171258A1 (es) | 2017-08-28 |
| EA201791632A1 (ru) | 2017-12-29 |
| MX2021006751A (es) | 2021-07-15 |
| HK1245125A1 (zh) | 2018-08-24 |
| WO2016118589A1 (en) | 2016-07-28 |
| MX2017009122A (es) | 2017-10-12 |
| MA41378A (fr) | 2017-11-28 |
| IL253499A0 (en) | 2017-09-28 |
| US9415008B2 (en) | 2016-08-16 |
| JP2018503687A (ja) | 2018-02-08 |
| AU2016209363A1 (en) | 2017-08-24 |
| CA2974125A1 (en) | 2016-07-28 |
| AU2016209363B2 (en) | 2021-02-04 |
| AU2021202784A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX374870B (es) | Inhalador de polvo seco. | |
| MX2021006751A (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
| CO2019008487A2 (es) | Compuesto de quinazolina | |
| MY198928A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| EA201370162A1 (ru) | Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| BR112018006206A2 (pt) | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa | |
| MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX2018008196A (es) | Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional. | |
| MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. | |
| BR112019001130A2 (pt) | uso de lactama e composição farmacêutica | |
| MX2017013634A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo. | |
| MY198201A (en) | A Combination Medicament Comprising Phenylephrine And Paracetamol | |
| AR102903A1 (es) | Inhalador de polvo seco | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| MX387252B (es) | EL USO DE DERIVADOS DE QUINOLINONAS QUE TIENE UNA ACTIVIDAD DE INHIBICIÓN DE LA FORMACIÓN DEL COMPLEJO DE C-Myc/Max/ADN EN EL TRATAMIENTO DE CANCER. | |
| TH173838A (th) | เครื่องพ่นละอองยาผงแห้ง | |
| UY35901A (es) | Nueva dosificación y formulación | |
| BR112017018977A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de uma infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, em um hospedeiro em necessidade do mesmo e para fabricação de um medicamento direcionado para uso terapêutico para tratamento de uma infecção pelo vírus da hepatite c, uso de um composto, e, formulação farmacêutica?. |